Menu
Search
|

Menu

Close
X

argenx SE ARGX.OQ (NASDAQ Stock Exchange Global Select Market)

148.02 USD
-2.49 (-1.65%)
As of Jul 19
Previous Close 150.51
Open 150.31
Volume 29,949
3m Avg Volume 47,804
Today’s High 150.31
Today’s Low 146.71
52 Week High 150.85
52 Week Low 63.81
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.62 Mean rating from 13 analysts

KEY STATS

Revenue
No Data Available
FY
-
FY
-
FY
-
FY
-
EPS
No Data Available
FY
-
FY
-
FY
-
FY
-

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.52
Price to Sales (TTM)
vs sector
--
7.97
Price to Book (MRQ)
vs sector
--
4.45
Price to Cash Flow (TTM)
vs sector
--
24.33
Total Debt to Equity (MRQ)
vs sector
--
17.60
LT Debt to Equity (MRQ)
vs sector
--
12.58
Return on Investment (TTM)
vs sector
--
12.69
Return on Equity (TTM)
vs sector
--
17.17

EXECUTIVE LEADERSHIP

Peter Verhaeghe
Non-Executive Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
Tim Van Hauwermeiren
Chief Executive Officer, Member of the Board, Since 2014
Salary: €303,941.00
Bonus: --
Werner Lanthaler
Non-Executive Independent Vice Chairman of the Board, Since 2014
Salary: --
Bonus: --
Eric Castaldi
Chief Financial Officer, Since 2014
Salary: €271,344.00
Bonus: --
Hans de Haard
Chief Scientific Officer, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Willemstraat 5
BREDA     4811 AH

Phone: +3176.3030488

argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.

SPONSORED STORIES